Literature DB >> 35733002

A qPCR-Based Method for Quantification of Replication Competent Adenovirus (RCA) in Conditionally Replicating Oncolytic Adenoviruses.

Erik Yngve1, Menghan Gao1, Di Yu2.   

Abstract

Production of conditionally replicating adenoviruses may unfortunately generate undesired replication-competent adenovirus (RCA) which raises safety concerns in clinical usage. Cell-based assays can detect RCA in batches of nonreplicating adenoviral vectors but cannot distinguish RCA from conditionally replicating oncolytic adenoviruses. Considering the great potential in using oncolytic viruses for cancer treatment, there is a need for comprehensive RCA-detection and -quantification methods. Here, we present a quantitative polymerase chain reaction (qPCR)-based assay that can be used to detect RCA particles in batches of conditionally replicating oncolytic adenoviruses. The assay is quantifying RCA by detection of the specific DNA sequence generated after a recombination event. Results showed that the method can successfully detect low levels of RCA, with a low limit of detection of ten viral particles.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Clinical production; Conditionally replicating adenovirus; Quantification; Replication competent adenovirus; qPCR

Mesh：

Year:  2022        PMID： 35733002     DOI： 10.1007/978-1-0716-2441-8_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  9 in total

1.  Who's afraid of replication-competent adenoviruses?

Authors:  F J Fallaux; A J van der Eb; R C Hoeben
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

2.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.

Authors:  C Heise; A Sampson-Johannes; A Williams; F McCormick; D D Von Hoff; D H Kirn
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

3.  Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line.

Authors:  N Louis; C Evelegh; F L Graham
Journal:  Virology       Date:  1997-07-07       Impact factor: 3.616

4.  Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (delta E1 + delta E3) during multiple passages in 293 cells.

Authors:  H Lochmüller; A Jani; J Huard; S Prescott; M Simoneau; B Massie; G Karpati; G Acsadi
Journal:  Hum Gene Ther       Date:  1994-12       Impact factor: 5.695

5.  Characterization of replication-competent adenovirus isolates from large-scale production of a recombinant adenoviral vector.

Authors:  J Zhu; M Grace; J Casale; A T Chang; M L Musco; R Bordens; R Greenberg; E Schaefer; S R Indelicato
Journal:  Hum Gene Ther       Date:  1999-01-01       Impact factor: 5.695

6.  Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer.

Authors:  Di Yu; Justyna Leja-Jarblad; Angelica Loskog; Per Hellman; Valeria Giandomenico; Kjell Oberg; Magnus Essand
Journal:  Neuroendocrinology       Date:  2016-07-21       Impact factor: 4.914

7.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.

Authors:  F J Fallaux; O Kranenburg; S J Cramer; A Houweling; H Van Ormondt; R C Hoeben; A J Van Der Eb
Journal:  Hum Gene Ther       Date:  1996-01-20       Impact factor: 5.695

8.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses.

Authors:  F J Fallaux; A Bout; I van der Velde; D J van den Wollenberg; K M Hehir; J Keegan; C Auger; S J Cramer; H van Ormondt; A J van der Eb; D Valerio; R C Hoeben
Journal:  Hum Gene Ther       Date:  1998-09-01       Impact factor: 5.695

Review 9.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.